Stock REGN34 REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Regeneron Pharmaceuticals, Inc. Sao Paulo

Equities

REGN34

BRREGNBDR005

Delayed Sao Paulo
Other stock markets
 12:13:02 2024-07-05 EDT 		5-day change 1st Jan Change
94.76 BRL +20.88% Intraday chart for Regeneron Pharmaceuticals, Inc. -2.32% +39.13%
07-03 Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval MT
07-03 Sanofi obtains EU approval for Dupixent RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sanofi - Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
AQ
REGENERON PHARMACEUTICALS, INC. - DUPIXENT APPROVED IN THE EUROPEAN UNION AS THE FIRST-EVER TARGETED THERAPY FOR PATIENTS WITH COPD
AQ
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
GL
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
AQ
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
REGENERON - ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA
AQ
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
GL
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
GL
Sanofi - Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
AQ
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
GL
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
AQ
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
GL
Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD
AQ
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GL
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. REGN34 Stock
  5. News Regeneron Pharmaceuticals, Inc.
  6. Press Releases